Preclinical Efficacy and Safety Data for hKGF-2 Eye Drops in Animal Models

732.6 KB document contains tabular results from two animal model studies assessing human keratinocyte growth factor-2 eye drops for dry eye disease. The data compares three hKGF-2 doses against positive controls across primary endpoints like tear secretion and corneal fluorescein staining. Safety pharmacology results from functional observation battery tests in rats and cardiovascular monitoring in dogs are included.

Use Cases

• Compare therapeutic effects across three hKGF-2 dosage groups (50, 100, 200 μg/mL) using primary endpoints like tear secretion measurement and corneal fluorescein staining.
• Analyze safety pharmacology results from the functional observation battery (FOB) in rats to assess central nervous system effects of hKGF-2 treatment.
• Evaluate cardiovascular and respiratory system impacts in Beagle dogs using monitored electrocardiogram (ECG), respiration (RESP), and blood pressure (BP) data.
• Determine the minimum effective dose (MED) of hKGF-2 by correlating dosage levels with outcomes on tear film break-up time (TBUT) and histopathologic examination.

Strengths

• Data includes results from two distinct animal models: a benzalkonium chloride-induced rabbit model and a scopolamine-induced rat model.
• Compares three experimental hKGF-2 doses (50, 100, 200 μg/mL) against two commercially available positive control medicines.
• Assesses multiple primary endpoints including tear secretion, corneal fluorescein staining, tear film break-up time, and histopathologic examination.
• Includes safety pharmacology assessments on central nervous, cardiovascular, and respiratory systems from separate rat and dog studies.

Limitations

• Dataset is a 732.6 KB DOCX file; underlying tabular data structure, row count, and column names are unknown.
• Data is derived from preclinical animal studies; direct applicability to human clinical outcomes is limited.
• Sample data is unavailable for inspection, preventing assessment of data granularity or completeness.

Provenance

Source

figshare, author Juan Li.

Collection Method

Primary pharmacodynamics and safety pharmacology studies conducted in rabbit and rat dry eye disease models, and in Beagle dogs.

Time Range

Treatment period was 21 days for the efficacy studies.

Freshness

Last updated March 25, 2026.

Geography

null